Native T1 mapping for the assessment of EOM fibrosis in TAO

Native T1 mapping for the assessment of extraocular muscle fibrosis in thyroid-associated ophthalmopathy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000040394

Enrollment

Unknown

Registered

2020-11-28

Start date

2020-12-01

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid-associated ophthalmopathy

Interventions

Gold Standard:Pathological Diagnosis

Index test:T1&#32

mapping&#32

and&#32

extracellular&#32

volume

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Subjects with Thyroid-associated ophthalmopathy; Subjects with intraocular tumor, end-stage glaucoma, or eyeball atrophy.

Exclusion criteria

Exclusion criteria: Subjects without pathological assessment.

Design outcomes

Primary

Measure	Time frame
Native T1 mapping;Extracellular Volume;	—

Countries

China

Contacts

Public ContactJiang Qian

Fudan Eye & ENT Hospital

qianjiang@fudan.edu.cn+86 21 64377134

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 21, 2026